Global Endometriosis Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2032

Endometriosis Market Analysis

Globally, there is a greater emphasis on women's diseases, and more and more innovative drugs and treatments are being introduced to alleviate their suffering. Endometriosis is one of the most common diseases, affecting approximately 170 million women worldwide. With such a large number of women suffering from endometriosis, significant advances in endometriosis treatment are being made by incorporating cutting-edge technologies. As there is a high demand for endometriosis treatment, significant efforts are being made to improve diagnosis methods. Most importantly, women all over the world are becoming more aware of their situation and vocal about it, making growth in this market highly profitable and significant.

Endometriosis Market Size

Global endometriosis market size was valued at USD 1.28 billion in 2024 and is projected to reach USD 1.85 billion by 2032, with a CAGR of 4.75% during the forecast period of 2025 to 2032.

Report Scope and Market Segmentation       

Endometriosis Market Definition

Endometriosis is a painful gynaecological disorder that occurs when endometriosis tissues, which normally line the uterus, spread beyond or outside the uterus, or on the ovaries and fallopian tubes. Endometriosis is characterised by painful intercourse, painful menstrual or menstrual irregularities.

Endometriosis Market Dynamics

Drivers

• Infectious disease outbreaks, as well as pandemics, are becoming more common.

The rising prevalence of endometriosis has raised patient awareness of endometriosis treatment options. With the increased occurrence of the disease, there is also a shift in emphasis in research and development. Furthermore, government agencies are investing in healthcare infrastructure to provide patients with better treatment options. As a result, more drugs and diagnostic equipment for the treatment of endometriosis are required, driving the market even further.

• Expansion of end use industries

The market is dominated by high-priced hormone-based therapeutics, which play an important role in the patient's treatment of endometriosis. As a result, companies such as Bayer and AbbVie offer patient assistance programmes, which help to reduce the cost burden on patients. The availability of patient assistance programmes for expensive drugs is expected to increase patient adherence to such drugs, which will drive the market over the forecast period.

Opportunities

APAC countries are highly profitable markets for the life sciences industry. For example, India has taken significant steps to establish itself as the world's leading major biopharmaceutical innovation hub, including encouraging public-private partnerships (PPPs) in biopharmaceutical RandD projects. South Korea is also working to establish itself as a global biotech hub, with a focus on biosimilars, vaccine manufacturing, and stem cell therapies. The growing demand for curative treatments for life-threatening diseases such as cancer and diabetes emphasises the importance of drug RandD and, as a result, the demand for pyrogen testing kits for effective quality testing and control. 

Restraints/Challenges

The lack of non-invasive diagnostic tests for endometriosis available in the market is a major factor restraining the market over the forecast period. Most people are terrified of the non-invasive diagnostics procedure and try to avoid it at all costs. However, more and more women are becoming aware of the importance of early detection of endometriosis and are unafraid to pursue such diagnostics.

This endometriosis market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the endometriosis market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Endometriosis Market Scope

Endometriosis market is segmented on the basis of type, treatment, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyse meagre growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.

 Type

• Superficial peritoneal lesion
• Endometrioma
• Deeply infiltrating endometriosis
• Others

Treatment

• Pain medication
• Hormone birth control
• Gonadotropin-releasing hormone (GNRH) analogues
• Aromatase inhibitors
• Others

Route of administration

• Oral
• Parenteral
• Others

End users

• Hospitals
• Homecare
• Speciality centres
• Others

 Distribution channel

• Hospital pharmacy
• Online pharmacy
• Retail pharmacy

Endometriosis Market Regional Analysis

The endometriosis market is analyzed and market size insights and trends are provided by country, type, treatment, route of administration, end-users and distribution channel as referenced above.

The countries covered in the endometriosis market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

Geographically, North America has the largest market share for the global endometriosis market due to the established regulatory framework, high demand for disease-specific treatment, increased adoption of newer technologies, the presence of refined healthcare infrastructure, and increased patient awareness level, as well as the high prevalence of endometriosis. Europe is regarded as the second fastest growing regional segment, owing to the presence of globally marketed players and a surge in population. Asia-Pacific dominates the market, owing to an increase in the number of generic manufacturers in the region as well as rising disposable income.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Endometriosis Market Share

The endometriosis market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to endometriosis market.

Endometriosis Market Leaders Operating in the Market Are:

• Akorn, Incorporated (U.S.)
• Pfizer Inc. (U.S.)
• GlaxoSmithKline plc (U.K.)
• Novartis AG (Switzerland)
• Mylan N.V. (U.S.)
• Teva Pharmaceutical Industries Ltd.(Israel)
• Sanofi (France)
• Boehringer Ingelheim International GmbH. (Germany)
• AstraZeneca (U.K.)
• Johnson & Johnson Private Limited (U.S.)
• Bayer AG (Germany)
• Merck & Co., Inc. (U.S.)
• Prestige Consumer Healthcare Inc. (U.S.)
• F. Hoffmann-La Roche Ltd. (Switzerland)
• Bristol-Myers Squibb Company (U.S.)
• Almirall, S.A (Spain)
• Zenomed Healthcare Private Limited (India)
• Cadila Pharmaceuticals (India)
• Astellas Pharma Inc. (Japan)
• Eli Lilly and Company (U.S.)

SKU-53495